.png)
Biotech Bulls & Breakthroughs
Welcome to Biotech Bulls & Breakthroughs! This brand new podcast from BioPharmCatalyst explores the dynamic world of biotech investing alongside long-time biotech trader Sheff from Sheff Station. Each month, we will be discussing current events in the biotech industry and how these events impact investors, as well as a discussion of upcoming catalysts in the biotech space.
Podcasting since 2025 • 15 episodes
Biotech Bulls & Breakthroughs
Latest Episodes
Biotech Investing: FDA One Pivotal Trial and 2Q Outlook | Biotech Bulls & Breakthroughs
In this episode, as the biotech earnings season continues, John Gagliano and Sheff Sheffield dive deep into the new FDA one pivotal trial as an alternative to the regulatory pathway, and what it means for trial timelines and company runways in ...
•
Season 2
•
Episode 4
•
37:53
.png)
Tackling Rare Genetic Diseases with Diagonal Therapeutics
In this episode, John Gagliano speaks with Eric Duhaime, Senior VP of Finance and Corporate Development at Diagonal Therapeutics, about the innovative approaches the company is taking in drug development, with a particular focus on clustering a...
•
Season 2
•
Episode 3
•
19:55
Talking Biotech: Biotech Stocks to Watch, Hedge Funds & More
In this episode, as the biotech earnings season continues, John Gagliano and Sheff Sheffield explore the importance of cash burn in biotech, the role of hedge funds, and the many catalysts expected by the end of the quarter.In this epis...
•
Season 2
•
Episode 2
•
1:15:22
Navigating the Future of Biotech: Insights from the JP Morgan Healthcare Conference 2026
In this episode, as the biotech landscape continues to evolve, the recent JP Morgan Healthcare Conference 2026 has set the stage for an exciting year ahead. John Gagliano and Sheff Sheffield delve into the key takeaways from the conference, exp...
•
Season 2
•
Episode 1
•
49:55
2025 Biotech Recap & Set Up For 2026
In this episode, John Gagliano and Chef Sheffield review the biotech landscape of 2025, discussing key trends, FDA clarity, and the impact of CRLs on investor confidence. They highlight significant companies and catalysts to watch as they trans...
•
Season 1
•
Episode 11
•
47:55
